"005.001" . "Farmakodynamick\u00E9 vlastnosti"@cs . . . . . "Farmakoterapeutick\u00E1 skupina: antidota.\nATC k\u00F3d: V03AB25\nFlumazenil, imidazobenzodiazepinov\u00FD deriv\u00E1t, je benzodiazepinov\u00FDm antagonistou, kter\u00FD kompetitivn\u011B inhibuje \u00FA\u010Dinky l\u00E1tek, kter\u00E9 p\u016Fsob\u00ED prost\u0159ednictv\u00EDm benzodiazepinov\u00FDch receptor\u016F.\nByla hl\u00E1\u0161ena neutralizace paradoxn\u00EDch reakc\u00ED benzodiazepin\u016F.\nV experimentech na zv\u00ED\u0159atech nebyly flumazenilem blokov\u00E1ny \u00FA\u010Dinky l\u00E1tek, kter\u00E9 nep\u016Fsobily prost\u0159ednictv\u00EDm benzodiazepinov\u00E9ho receptoru (nap\u0159. barbitur\u00E1ty, GABA-mimetika a agonist\u00E9 adenosinov\u00E9ho receptoru). Nebenzodiazepinov\u00ED agonist\u00E9, nap\u0159. cyklopyrrolony (zopiklon) a triazolopyridaziny), jsou flumazenilem blokov\u00E1ni. Hypnosedativn\u00ED \u00FA\u010Dinky benzodiazepin\u016F jsou rychle blokov\u00E1ny (do 1 \u2013 2 minut) po intraven\u00F3zn\u00EDm pod\u00E1n\u00ED flumazenilu.\nV\u00A0z\u00E1vislosti na rozd\u00EDlu v\u00A0d\u00E9lce eliminace mezi agonistou a antagonistou se \u00FA\u010Dinek m\u016F\u017Ee po n\u011Bkolika hodin\u00E1ch vr\u00E1tit. Flumazenil m\u016F\u017Ee vykazovat slab\u00FD agonistick\u00FD, antikonvulzivn\u00ED \u00FA\u010Dinek. U zv\u00ED\u0159at, kter\u00FDm byly benzodiazepiny pod\u00E1v\u00E1ny po n\u011Bkolik t\u00FDdn\u016F ve vysok\u00FDch d\u00E1vk\u00E1ch, vyvolal flumazenil symptomy z n\u00E1hl\u00E9ho vysazen\u00ED, v\u010Detn\u011B k\u0159e\u010D\u00ED. \n"@cs . . .